# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Stephens & Co. analyst Mason Carrico maintains Pacific Biosciences (NASDAQ:PACB) with a Overweight and lowers the price ...
Morgan Stanley analyst Tejas Savant maintains Pacific Biosciences (NASDAQ:PACB) with a Equal-Weight and lowers the price tar...
Cantor Fitzgerald analyst Ross Osborn reiterates Pacific Biosciences (NASDAQ:PACB) with a Overweight and maintains $3.5 pric...
Canaccord Genuity analyst Kyle Mikson maintains Pacific Biosciences (NASDAQ:PACB) with a Buy and lowers the price target fro...
Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $...